Hims & Hers Health Soars 39.78% on Wegovy Partnership

On April 29, 2025, Hims & Hers Health surged 39.78% in pre-market trading, marking a significant rise in its stock price.

Hims & Hers Health has recently partnered with Novo Nordisk to offer Wegovy, a weight loss drug, through its telehealth platform. This collaboration allows customers to access all dose strengths of Wegovy along with a membership starting at $599 per month. The partnership aims to provide comprehensive healthcare services, including clinical support and nutrition guidance, to help patients manage obesity more effectively.

Novo Nordisk is expanding its efforts to sell Wegovy directly to patients by collaborating with telehealth companies, including Hims & Hers Health. This move is part of a broader strategy to increase patient access to authentic, FDA-approved medications through telehealth providers. The companies are developing a roadmap to combine Novo Nordisk's innovative medications with Hims & Hers' ability to deliver quality care at scale, with the goal of improving long-term outcomes for patients living with chronic diseases.